Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells

Endocrinology

Volumn 149, Issue 7, 2008, Pages 3626-3634

  Borgogni, E ^a   Sarchielli, E ^a   Sottili, M ^a   Santarlasci, V ^a   Cosmi, L ^a   Gelmini, S ^a   Lombardi, A ^a   Cantini, G ^a   Perigli, G ^a   Luconi, M ^a   Vannelli, G B ^a   Annunziato, F ^a   Adorini, L ^b   Serio, M ^a   Crescioli, Clara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BioXell SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; ELOCALCITOL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THIAMAZOLE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC ANALYSIS; GOITER; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CELL;

BLOTTING, WESTERN; CALCITRIOL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; METHIMAZOLE; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, INTERFERON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46349105011     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0078     Document Type: Article

References (55)

1. Aniszewski JP, Valyasevi RW, Bahn RS 2000 Relationship between disease duration and predominant orbital T cell subset in Graves' disease. J Clin Endocrinol Metab 85:776-780
2. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 161:195-206
3. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 91:614-620
4. Zlotnik A, Yoshie O 2000 Chemokines: a new classification system and their role in immunity. Immunity 12:121-127
5. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferranini E, Serio M 2006 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 154:651-658
6. Rotondi M, Lazzeri E, Romagnani P, Serio M 2003 Role for interferon-γ inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 26:177-180
7. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P 2007 Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492-520
8. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499
9. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M 2005 Increase of interferon-γ inducible α chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-177
10. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-γ-inducible α-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92:1485-1490
11. Antonelli A, Fallai P, Rotondi M, Ferrari SM, Serio M, Miccoli P 2006 Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93:1226-1231
12. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207-213
13. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 86:5008-5016
14. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M 2007 Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 195:145-155
15. Volpé R 2001 The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 7:451-460
16. Laurberg P 2006 Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism. Eur J Endocrinol 155:783-786
17. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M 2006 Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 64:189-195
18. Inukai Y, Momobayashi A, Sugawara N, Aso Y 2007 Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 156:623-630
19. Adorini L, Amuchastegui S, Corsiero E, Laverny G, Le Meur T, Penna G 2007 Vitamin D receptor agonists as anti-inflammatory agents. Expert Rev Clin Immunol 3:477-489
20. Arnson Y, Amital H, Shoenfeld Y 2007 Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66:1137-1142
21. Adorini L 2005 Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 233:115-124
22. Pinette V, Yee YK, Amegadzie BY, Nagpal S 2003 Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3:193-204
23. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E, Adorini L, Maggi M 2004 Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150:591-603
24. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M 2007 Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 103:689-693
25. Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trinchieri G, Reed SG 1995 A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 181:1527-1537
26. Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M 1999 Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 10:2518-2526
27. Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, Cosmi L, Maggi E, Romagnani S, Annunziato F 2007 Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 120:429-436
28. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S 2002 Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 196:379-387
29. ΔΔCt method. Methods 25:402-408
30. Crescioli C, Maggi M, Vannelli GB, Ferruzzi P, Granchi S, Mancina R, Muratori M, Forti G, Serio M, Luconi M 2003 Expression of functional estrogen receptors in human fetal male external genitalia. J Clin Endocrinol Metab 88:1815-1824
31. Vannelli GB, Ensoli F, Zonefrati R, Kubota Y, Arcangeli A, Becchetti A, Camici G, Barni T, Thiele CJ, Balboni GC 1995 Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. J Neurosci 15:4382-4394
32. De Lean A, Munson PJ, Rodbard D 1978 Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97-E102
33. Kidd P 2003 Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8:223-246
34. Tellides G 2006 Th1 adaptive immune responses in cardiac graft arteriosclerosis: deleterious or beneficial? Circulation 114:1561-1564
35. Campbell JD, Gangur V, Simons FE, HayGlass KT 2004 Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J 18:329-331
36. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S 2004 CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25:201-209
37. Chen K, Wei Y, Alter A, Sharp GC, Braley-Mullen H 2005 Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis. J Leukoc Biol 78:716-724
38. El-Sawy T, Fahmy NM, Fairchild RL 2002 Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 14:562-568
39. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P 2002 Differential expression of the IFN-γ-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell α chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 169:1556-1560
40. Klingenberg R, Autschbach F, Gleissner C, Giese T, Wambsganss N, Sommer N, Richter G, Katus HA, Dengler TJ 2005 Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro. Eur J Immunol 35:1712-1721
41. Lazzeri E, Romagnani P 2005 CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5:109-118
42. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N 2002 Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169:2685-2693
43. Vidal M, Ramana CV, Dusso AS 2002 Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 22:2777-2787
44. Matsuzaki J, Tsuji T, Zhang Y, Wakita D, Imazeki I, Sakai T, Ikeda H, Nishimura T 2006 1α,25-Dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation. Cancer Sci 97:139-147
45. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L 2004 A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 173:2280-2287
46. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L 2007 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178:145-153
47. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P 2002 Serum concentrations of tumour necrosis factor-α (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57:515-521
48. Wang SH, Van Antwerp M, Kuick R, Gauger PG, Doherty GM, Fan YY, Baker Jr JR 2007 Microarray analysis of cytokine activation of apoptosis pathways in the thyroid. Endocrinology 148:4844-4852
49. Crescioli C, Squecco R, Cosmi L, Sottili M, Gelmini S, Borgogni E, Sarchielli E, Scolletta S, Francini F, Annunziato F, Vannelli GB, Serio M 2008 Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 314:1337-1350
50. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, Doglioni C, Adorini L 2006 Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 77:8504-8511
51. Stockinger B 2007 Th17 cells: an orphan with influence. Immunol Cell Biol 85:83-84
52. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S 2007 Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849-1861
53. Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y 2008 Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 93:1077-1081
54. McLachlan SM, Nagayama Y, Rapoport B 2005 Insight into Graves' hyperthyroidism from animal models. Endocr Rev 26:800-832
55. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE 2007 Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634-1647